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Impotence is one of the common complications after the radical prostatectomy. One of the main
reasons of this complication is due to the dysfunction of the veins in corpus cavernosum. Recent
studies have shown that the erectile function is improved after the long-term therapy of
phosphodiesterase type 5 inhibitor among patients with post-prostatectomy erectile dysfunction.
In this study, we evaluated the effects of mirodenafil on the penile erection and corpus cavernosum
tissues in the rat model of cavernosal nerve injury. Rats were divided into four groups: (1) control
group, (2) bilateral cavernosal nerve injury group, (3) mirodenafil 10mg therapy group after the
nerve injury and (4) mirodenafil 20mg therapy group after the nerve injury. After we identified
the nerve from the pelvic nerve complex on the lateral side of the prostate, the rats in the control
group were sutured without causing any nerve injury and in other groups we damaged the nerve
by compressing it with a vessel clamp. Then, 10 and 20mgkg
 1 of mirodenafil were orally
administered to two experimental groups. After 8 weeks, the intracavernosal pressure (ICP) was
recorded. The immunohistochemical staining and western blot were performed, and the effect of
mirodenafil on the expression of cyclic guanosine monophosphate (cGMP) was evaluated through
enzyme-linked immunosorbent assay. The ICP of nerve-injured group was decreased compared
with the control group; however, the ICP of the mirodenafil-administered groups was improved
compared with the nerve-injured group. The Masson’s trichrome staining confirmed that the
smooth muscle (SM) component was increased in the mirodenafil-administered groups. The nitric
oxide synthase expression and cGMP of mirodenafil-administered groups was increased compared
with the nerve-injured group. Long-term therapy of mirodenafil may improve the erectile function
after the radical prostatectomy by preserving the SM content and inhibiting the fibrosis of the
corpus cavernosum.
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Introduction
With the advancement in early detection of the
prostate cancer, radical prostatectomy has been
frequently performed. Although more surgical
advances in prostatectomy such as robot-assisted
surgery have been made, complications such as
erectile dysfunction and urinary incontinence
occur frequently after the radical prostatectomy.
1,2
Moreover, the number of patients who experience
the postsurgical complications is gradually increasing,
despite the fact that the patient’s age at the time of
prostate cancer diagnosis is decreasing. The factors
that affect the occurrence of the postsurgical
complications are surgical dexterity, degree of
anatomical variability and progression of disease.
For the prevention of the post-prostatectomy
erectile dysfunction, many surgical procedures
and modalities are being researched and developed.
For instance, sparing nerves in the vicinity of
the prostate during the radical prostatectomy was
considered to reduce the complications.
3 In cases
in which the nerve sparing surgery is not indicated,
erectile dysfunction and other complications do
frequently occur. Nevertheless, more than half of the
patients who received the nerve-sparing opera-
tions complained of a partial erectile dysfunction.
4
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www.nature.com/ijirThe primary cause of this phenomenon was because
of the corporal veno-occlusive dysfunction, which
is the inability of the corporal smooth muscle (SM)
cells to relax sufficiently to attain intracorporal
pressure great enough to adequately compress the
subtunical veins and prevent venous leakage.
5,6
In terms of treating the erectile dysfunction,
recent studies have shown that a long-term use
of phosphodiesterase type 5 (PDE5) inhibitors
improves the erectile function.
7–9 Treatment agents
for the erectile dysfunction include sildenafil,
tadalafil, vardenafil and udenafil. Up to this date,
only a small number of studies have reported their
effects on the erectile dysfunction from any kinds of
nerve injury. One of the recently developed PDE5
inhibitors, mirodenafil, has been reported to have
an excellent profile of the efficacy for the erectile
dysfunction; yet, there are no studies confirming
its effects on the erectile function among post-
prostatectomy patients.
10–13 In an animal experimental
model of the nerve injury in corpus cavernosum,
we administered mirodenafil to evaluate its effects
on the erectile function and corpus cavernosum
tissues. These results would serve as the foundation
for the possibility of administering mirodenafil and
other PDE5 inhibitors in treating patients with post-
prostatectomy erectile dysfunction.
Materials and methods
Materials
White male Sprague–Dawley rats aged 16 weeks
with weight distribution of 300–350g were pur-
chased from Samtako Inc. (Osan, Korea). Then, the
rats were divided into four groups: the control group
(n¼10, group 1), the bilateral nerve injury group
(n¼10, group 2), the mirodenafil 10mgkg
 1 admi-
nistered group after the bilateral nerve injury
(n¼10, group 3, M10 group) and the mirodenafil
20mgkg
 1 administered group after the bilateral
nerve injury (n¼10, group 4, M20 group).
Experimental animals
Tiletamine (Zoletil) 0.2ml was intra-abdominally
injected to anesthetize the animals. A median
incision was made on the lower abdomen, thereby
exposing the urinary bladder and prostate. After
identifying the location of pelvic nerve plexus on
the lateral side to bilateral prostates, the poster-
olateral nerve branch was dissected. The nerve was
damaged by compressing it for 2min. Technically in
the strict sense, we damaged the nerve by compres-
sing it with a clamp (nerve crush), rather than
severing the nerve as other studies have injured the
nerve (nerve cutting). In group 1 (control group),
same procedure was carried out for identifying the
nerve plexus and the suture was performed without
causing any nerve injury. In group 2 (nerve injury
group or BCNX group), the suture was performed
after causing the nerve injury. Mirodenafil (SK
Chemicals, Suwon, Korea) was dissolved in drink-
ing water as described previously.
10 Mirodenafil was
dissolved in 40% PEG solution in water and the rats
were fasted overnight before drug administration
and until 6h after dosing. The drinking volume and
the body weight were recorded daily.
In group 3 (M10 group), 10mgkg
 1 of mirodenafil
was orally administered. In group 4 (M20 group),
twice the dosage of mirodenafil (20mgkg
 1) was
orally administered. After 8 weeks, erectile function
was measured using the intracavernosal pressure
(ICP). Corpus cavernosum tissue sampling was
performed followed by the Masson’s trichrome
staining, NOS expression (western blot) and cyclic
guanosine monophosphate (cGMP) analysis.
ICP measurement
The rats were anesthetized with an intraperitoneal
injection of 0.2ml tiletamine (Zoletil). With the rat
in the supine position, the penis was dissected and
the corpus cavernosum and crus of the penis were
exposed. A low, midline abdominal incision was
made to access the pelvis, and the pelvic ganglion
lateral to the right prostate was exposed. For the
measurement of the ICP, a heparinized 23G butterfly
needle was inserted in the corpus cavernosum of
penile proximal portion after penile skin was
degloved and the corpus cavernosum identified.
Then a bipolar electrical stimulator was placed on
the ganglion to stimulate the cavernosal nerve for
50s at 10V and 2.4mA for 0.5ms. The cavernosal
nerve stimulation was conducted at least three times
and the interval between stimulations was main-
tained for over 10min. After the stimulation test, the
corpus cavernosum was removed and divided into
two. The first part was cryopreserved in liquid
nitrogen and the other part was fixed in formalin. To
compare the erections of the control and experi-
mental groups, we recorded the peak ICP. The ‘drop
rate’ was determined by recording the decrease in
ICP within the next 1min after the infusion was
stopped.
Masson’s trichrome staining
After cavernosometry, the skin denuded middle
part of the penile shafts were fixed overnight in
10% formalin, washed and stored in 70% alcohol
at 41C until processed for paraffin-embedded tissue
sectioning (5mm). The cavernosal tissue was
obtained for the Masson’s trichrome staining. After
staining, the color distribution of the muscle tissue
was approximated by using the Adobe Photoshop
CS 8.0 (San Jose, CA, USA). After the entire color
distribution of the image was calculated, we
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the color red. There were somewhat standard
deviations in our calculation because of color over-
lays and ambiguity of the color spectrum of the
muscle tissues.
eNOS and nNOS protein expression tests: western
blot
The skin, dorsal vein and urethra of all rats were
removed. The corpus cavernosum was obtained
from all rats and homogenized individually in a
buffer solution of 0.32 M sucrose, 0.2 M HEPES (pH
7.4), 1mM ethylenediaminetetraacetic acid, 1mM
dithiothreitol, 10mgml
 1 leupeptin, 2mgml
 1 apro-
tinin, 1mgml
 1 pepstatin, 10mgml
 1 trypsin inhibi-
tor and 1mM phenylmethylsulfonyl fluoride. The
homogenized buffer solution was placed on ice for
15min and centrifuged at 41C for 13000r.p.m. for
15min. The supernatant solution was separated.
The separated solution was used in the bovine
serum albumin. Quantitative protein (30mg) was
denatured at 951C for 5min and electrophoresis was
performed on a 12% discontinuous SDS–polyacryl-
amide gel. The proteins were then electroblotted
onto a 0.2mm polyvinylidene difluoride (Amersham
Biosciences, Piscataway, NJ, USA) membrane for
150min at 25V. The membranes were reacted with
blocking buffer (5% skim milk in TBS-T buffer) for
30min at the ambient temperature. The endothelial
NOS (eNOS) and neuronal NOS (nNOS) (BD
Biosciences, San Diego, CA, USA) antibodies were
added for 2h, and the membrane was washed three
times using TTBS at intervals of 10min. As the
secondary antibodies, anti-mouse IgG-HRP and anti-
goat IgG-HRP (1:2000 dilution) (Zymed Laboratories,
San Francisco, CA, USA), were added at the ambient
temperature for 1h and the membrane was washed
again with TTBS for six times with an interval of
5min between each washing. Chemiluminescence
was detected using ECL western blotting detection
reagents. Densitometric assessment of the bands on
the autoradiogram was performed using Bio1D software
(version 97; Vilber Lourmat, Marne-la-Valle ´e, France).
cGMP analysis
The corpora cavernosa was immediately frozen in
liquid nitrogen. The frozen sample was homoge-
nized in cold 6% (w/v) trichloroacetic acid at 2–81C
to produce a 10% (w/v) homogenate. Each homo-
genized penis sample was centrifuged at 2000 g for
15min at 41C and recovered the supernatant. The
supernatant was washed four times with 5 volumes
of water saturated diethyl ether and dried at 601C.
The dried extract was dissolved in a suitable volume
of assay buffer before analysis. After the dissolution,
the samples were assayed for cGMP by using a
cGMP competitive enzyme immunoassay kit (Biotrak;
Amersham Pharmacia Biotech UK, Bucks, UK).
Statistical analysis
All the measurements were expressed as mean±
standard deviation (s.d). Statistical analysis was
obtained through Sigma stat for Windows. An inter-
group comparison was made with the use of
Newman–Keuls multiple comparison test. The cut-
off value of statistical significance was Po0.05.
Results
Changes in the erectile function after the nerve
injury
The erectile function was measured 8 weeks after
the nerve injury. As a result, the erectile function
was decreased in the nerve injury group (drop rate,
31±2.3mmHgmin
 1) compared with the control
group (9±1.5mmHgmin
 1; Po0.05) (Table 1).
Changes in the erectile function after the
administration of mirodenafil
The erectile function was measured 8 weeks after the
nerve injury. The erectile function was significantly
improved in mirodenafil treatment groups, M10
group (15±5.9mmHgmin
 1) and M20 group (12±
6.9mmHgmin
 1), compared with the nerve injury
group (31±2.3mmHgmin
 1; Po0.05) (Table 1).
Decreased muscle content and increased collagen
content
On the Masson’s trichrome staining, the muscle
content was decreased and collagen content was
increased in the nerve injury group as compared
with the control group (Figure 1, Table 2). In the
mirodenafil-administered groups (10.6±5, 14.0±7),
the muscle/collagen ratio was higher than the nerve
injury group (6.0±3) (Figure 1, Table 2).
Quantification of eNOS and nNOS proteins
In all groups, the expression of NOS against actin
was different and so we needed the correction to
compare the expression of NOS. We corrected the
Table 1 Changes of ICP at 8 weeks after cavernosal nerve injury
Flaccid ICP
(mmHg)
ICP after
papaverine (mmHg)
Drop rate
(mmHgmin
 1)
Mean s.d. Mean s.d. Mean s.d.
Control 9 2.2 80 5.8 9 1.5
BCNX 7 1.1 55 6.7 31
a 2.3
M10 11 2.0 61 5.4 15
b 5.9
M20 14 2.4 68 6.3 12
b 6.9
aSignificantly increased (Po0.05) compared with control group.
bSignificantly decreased (Po0.05) compared with BCNX group.
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compared the expression of NOS. eNOS and nNOS
proteins were decreased by western analysis in the
nerve crush group as compared with the control
group, and levels increased in the mirodenafil
treatment groups (Figures 2 and 3) (Po0.05).
Effect of mirodenafil on cGMP
cGMP was significantly decreased in the nerve
injury group (20.8±5.0fmol per well) compared
Figure 1 Masson’s trichrome staining for collagen (blue) and smooth muscle ( 100). Control group, normal group; BCNX group,
cavernosal nerve injury group; M10 group, mirodenafil 10mgkg
 1 administered group intake after cavernosal nerve injury; M20 group,
mirodenafil 20mgkg
 1 administered group after cavernosal nerve injury.
Table 2 Muscle distribution (muscle/collagen ratio) at 8 weeks
after cavernosal nerve injury
Muscle distribution (muscle/collagen ratio)
Group Mean (%) s.d.
Control 13.8 7
BCNX 6.0 3
M10 10.6 5
M20 14.0 7
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15.7fmol per well) and in M20 group (59.8±
17.0fmol per well) was increased compared with
the nerve injury group (Figure 4) (Po0.05).
Discussion
Neurotransmitters that induce the penile erection
are nitric oxide (NO), acetylcholine, substance P,
vasoactive intestinal peptide and adenosine triphos-
phate in the penile nerve; and NO, prostaglandin
and bradykinin in the corpus cavernosum.
14,15
Specifically, NO is known as the most important
neurotransmitter that mediates the relaxation of
SM layer present in the corpus cavernosum.
16,17
Synthesized within the vascular endothelium, NO
is an endothelium-derived relaxation factor in
which nitric oxide synthase (NOS) has an important
role in its metabolism. NO is diffused through
the cell membrane and activates guanylate cyclase
SM in vessel in the adjacent corpus cavernosum.
Consequently, it increases the synthesis of cGMP,
mediating the relaxation of corpus cavernosum.
17
It has been reported that constitutive NOS (eNOS)
and inducible NOS are located within the vascular
endothelium.
18 It is known that inducible NOS
directly decreases collagen deposition or sup-
presses the formation of profibrotic reactive
oxygen species, thereby having an anti-fibrotic
effect.
19,20 The role of NOS has been frequently
examined in association with the erectile dysfunc-
tion after the extensive prostatectomy. Causative
factors for the erectile dysfunction after the prosta-
tectomy are based on the functional insufficiency of
veins distributed in the corpus cavernosum. That is,
due to an insufficient extent of the relaxation of
corpus cavernosum, the pressure within the corpus
cavernosum cannot be increased to such an extent
that its leakage into penile vein can be prevented.
5
The pathophysiological etiology of the erectile
dysfunction originates from the nerve injury that is
caused during prostatectomy. Even after a nerve-
conserving operation, the erectile dysfunctions
do frequently occur. One cause of these erectile
dysfunctions is the physiologic nerve block as
known the neuropraxia and the other is penile
fibrosis after hypoxemia.
5,6,21 The injury of nerves
innervating corpus cavernosum was developed
during the dissection of prostate, which caused the
physiologic nerve block and the postoperative
occurrence of erectile dysfunction, thereof.
5,6 On
recent prospective study of nerve-sparing radical
prostatectomy patients, postoperative prophylactic
PGE1 were more likely to improve erectile function
than placebo.
22 In this study, although psychogenic
effects cannot be ruled out, up to 28% of patients
in one study using intracorporal PGE1 achieved
improved spontaneous erections and less frequent
need for intracorporal injections. Taken together,
this study suggests a role of hypoxemia in penile
fibrosis and a role for and in preserving a functional
Figure 2 The expression of NOS at 8 weeks after cavernosal
nerve injury.
Figure 3 The expression of NOS at 8 weeks after cavernosal
nerve injury. *Significantly different (Po0.05) from the BCNX
group. **Significantly different (Po0.05) from the BCNX group.
Figure 4 The effect of mirodenafil on cGMP at 8 weeks
after cavernosal nerve injury. *Significantly increased (Po0.05)
compared with BCNX group. **Significantly increased (Po0.05)
compared with BCNX group.
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nosum. The authors thought the muscle/collagen
ratio is important for the erectile function. In
our study, the ICP and muscle/collagen ratio of
nerve injury group were lower than mirodenafil-
administered groups and these results indirectly
improved that. Conclusively, due to a depletion of
oxygen supply within the corpus cavernosum and
the occurrence of fibrosis of corpus cavernosum,
venous-blocking erectile dysfunction eventually
occurs. Because erectile dysfunction after the
prostatectomy may lower the quality of life conse-
quently, many patients refuse to receive the surgery.
Recent studies have reported that a long-term use of
PDE5 inhibitor showed effectiveness among patients
who complained of erectile dysfunction after
the prostatectomy.
7,8 Also, there were animal
studies that attempted to show the effects of the
PDE5 inhibitors in treating the erectile dysfunction.
9
These results proposed the possibility that a
recovery of erectile function could be achieved by
preventing NOS-induced fibrosis and increasing
muscle fibers after the prostatectomy. Monica and
co-workers
9 dissected bilateral corpus cavernosum
nerves in rats and resected ancillary branches at a
length of 5mm, thereby creating an animal experi-
mental model of erectile dysfunction that was
similar to that seen after prostatectomy. The dose
of vardenafil corresponding to 20mg in humans
was calculated based on the surface area of rats. This
was followed by a 45-day administration. ICP
was measured 45 days later, which showed that
the drop rate was 42±5mmHgmin
 1 in the nerve
injury group, 18±2 in the control group and 17±2
in the vardenafil treatment group. In our study, the
results showed that ICP of the nerve injury group
(7±1.1mmHg) decreased (9±2.2mmHg) and the
drop rate increased compared with the control
group (nerve injury group, 31±2.3mmHgmin
 1;
control group 9±1.5mmHg) (Po0.05). The results
also showed that ICPs of mirodenafil-administered
groups (11±2.0 and 14±2.4mmHg) increased and
drop rates decreased compared with the nerve
injury group (Po0.05). These results indicate that
the administration of PDE5 inhibitor group showed
a remarkable improvement in the erectile function.
On the Masson’s trichrome staining, an increase in
the muscle fibers present within corpus cavernosum
and a decrease in collagen synthesis were observed.
9
In our study, mirodenafil-administered groups’
muscle/collagen ratio was increased compared to
the nerve injury group. These results were also in
agreement with the studies mentioned above, which
were indicative of the effects of PDE5 inhibitor after
the nerve injury. The presumptive mechanisms are
based on the increased synthesis of cGMP and
the resulting decrease of auto-apoptosis of muscle
cells and prevention of collagen deposition. Accord-
ing to the experiments performed by Monica and
co-workers,
9 however, the nerve was dissected and
the secretion of NOS was impossible on a theoretical
basis. Nevertheless, the causative factors explaining
these phenomena could not be identified. It has
been hypothesized that they originated from the
nerve regeneration and the effects of materials that
have not been disclosed up to present. In our study,
the nerve dissection was not performed and the
nerve injury was only conducted by the compres-
sion, which were different from the experimental
results reported by Monica and co-workers.
9 Hence-
forth, further studies are warranted to examine the
results after the nerve dissection.
Conclusion
In our study, the nerve injuries on both sides of
corpus cavernosum significantly reduced the erec-
tile function and expression level of NOS and cGMP.
After the administration of mirodenafil, the erectile
function and the expression of NOS and cGMP
were improved. These results serve as the founda-
tion for the future mirodenafil treatment of post-
prostatectomy erectile dysfunction patients.
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